Information de reference pour ce titreAccession Number: | 00078447-201010150-00018.
|
Author: | Luo, Yun a; Ling, You b; Guo, Wusheng b; Pang, Jun a; Liu, Weipeng a; Fang, Youqiang a; Wen, Xinqiao a; Wei, Kun b,*; Gao, Xin a,*
|
Institution: | (a)Department of Urology, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China (b)College of Materials Science and Engineering, South China University of Technology, Guangzhou 510640, China
|
Title: | Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.[Article]
|
Source: | Journal of Controlled Release. 147(2):278-288, October 2010.
|
Abstract: | : Docetaxel (Dtxl) remains the preferred choice of improving the survival of patients with hormone refractory prostate cancer (HRPC), but many patients suffer from modest drug response and significant toxicity. In the present study, we investigated the efficiency of novel Dtxl loaded-[1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-carboxy(polyethylene glycol)]2000 (DSPE-PEG-COOH) stabilized-oleic acid (OA) coated hydroxyapatite (HA) nanoparticles (Dtxl-NPs) and gained insights into the molecular mechanism of the apoptosis induced by these novel Dtxl-loaded nanoparticles. The drug encapsulation efficiency of Dtxl was 83.6% and the sustained drug release was observed over 30 days. The Dtxl-NPs exhibited significantly more cytotoxicity in both prostate cancer cell lines (PC3 and DU145) compared with Dtxl in vitro and increased the Dtxl-induced apoptosis in the PC3 cells. Cell cycle analysis showed that the PC3 cells treated with Dtxl-NPs exhibited significant arrest in the G2-M phase but a higher sub-G0/G1 population when compared with Dtxl. The enhanced apoptosis induced by Dtxl-NPs in the PC3 cells was associated with the changes in mitochondrial membrane potential (MMP) and seemed to involve the activation of caspase-2. The kinetic studies of caspases demonstrated an early activation of caspase-2 in Dtxl-NPs-induced apoptosis in PC3 cells, which differs from Dtxl-induced apoptosis. The inhibition of caspase-2 activation by small interfering RNA (siRNA) knockdown resulted in the significant inhibition of Dtxl-NPs-induced disruption of MMP and Dtxl-NPs-induced apoptosis, indicating that the activation of caspase-2 was the critical event before the mitochondrial depolarization in the PC3 cells. Our findings showed that nanoparticles, more than simple drug carriers, may play an active role in mediating the biological effects.
(C) 2010Elsevier, Inc.
|
Author Keywords: | Hydroxyapatite; Nanoparticle; Docetaxel; Prostate cancer; Apoptosis; Caspase.
|
References: | [1]. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M.J. Thun, Cancer statistics, 2009. CA Cancer J. Clin 59 (4) (2009), 225-249.
[2]. J.A. Rumohr, S.S. Chang, Current chemotherapeutic approaches for androgen-independent prostate cancer. Curr. Opin. Investig. Drugs 7 (6) (2006), 529-533.
[3]. F. Lavelle, F. Gueritte-Voegelein, D. Guenard, Taxotere: from yew's needles to clinical practice. Bull. Cancer 80 (4) (1993), 326-338.
[4]. M.J. Piccart, Taxanes: an action mechanism at the cellular level, significant clinical progress in the treatment of cancers of the ovary and breast. Bull. Mem. Acad. R. Med. Belg 153 (5-6) (1998), 285-292, discussion 292-294.
[5]. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, S. Oudard, C. Theodore, N.D. James, I. Turesson, M.A. Rosenthal, M.A. Eisenberger, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med 351 (15) (2004), 1502-1512.
[6]. J. Picus, M. Schultz, Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin. Oncol 26 (5 suppl 17) (1999), 14-18.
[7]. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara Jr, J.A. Jones, M.E. Taplin, P.A. Burch, D. Berry, C. Moinpour, M. Kohli, M.C. Benson, E.J. Small, D. Raghavan, E.D. Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med 351 (15) (2004), 1513-1520.
[8]. U. Vaishampayan, M. Hussain, Update in systemic therapy of prostate cancer: improvement in quality and duration of life. Expert Rev. Anticancer Ther 8 (2) (2008), 269-281.
[9]. V.J. Assikis, J.W. Simons, Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin. Oncol 31 (2004) 26-32.
[10]. A.S. Retter, J.L. Gulley, W.L. Dahut, Novel therapeutic strategies in prostate cancer. Cancer Biol. Ther 3 (4) (2004), 371-376.
[11]. J. Kopecek, Smart and genetically engineered biomaterials and drug delivery systems. Eur. J. Pharm. Sci 20 (1) (2003), 1-16.
[12]. R. Duncan, Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm. Sci. Technol. Today 2 (11) (1999), 441-449.
[13]. H. Shen, X. Hu, F. Yang, J. Bei, S. Wang, An injectable scaffold: rhBMP-2-loaded poly(lactide-co-glycolide)/hydroxyapatite composite microspheres. Acta Biomater 6 (2) (2010), 455-465.
[14]. J. Huang, Y.W. Lin, X.W. Fu, S.M. Best, R.A. Brooks, N. Rushton, W. Bonfield, Development of nano-sized hydroxyapatite reinforced composites for tissue engineering scaffolds. J. Mater. Sci. Mater. Med 18 (11) (2007), 2151-2157.
[15]. A. Hideki, O. Masataka, Effects of Adracin-adsorbing HAP-sol on Ca-9 cell growth. Reports Institute Med. Dental Eng 27 (1993) 39-44.
[16]. C.A. Stein, Mechanisms of action of taxanes in prostate cancer. Semin. Oncol 26 (5 suppl 17) (1999), 3-7.
[17]. K.G. Wolter, Y.T. Hsu, C.L. Smith, A. Nechushtan, X.G. Xi, R.J. Youle, Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol 139 (5) (1997), 1281-1292.
[18]. Z.S. Liu, S.L. Tang, Z.L. Ai, Effects of hydroxyapatite nanoparticles on proliferation and apoptosis of human hepatoma BEL-7402 cells. World J. Gastroenterol 9 (9) (2003), 1968-1971.
[19]. G. Li, J. Huang, Y. Li, R. Zhang, B. Deng, J. Zhang, H. Aoki, In vitro study on influence of a discrete nano-hydroxyapatite on leukemia P388 cell behavior. Biomed. Mater. Eng 17 (5) (2007), 321-327.
[20]. Y.J. Wang, C. Lai, K. Wei, X.F. Chen, Y. Ding, Z.L. Wang, Investigations on their formation mechanism of hydroxyapatite synthesized by solvothermal method. Nanotechnology 17 (2006) 4405-4412.
[21]. K. Wei, Y.J. Wang, C. Lai, C.Y. Ning, D.X. Wu, N.R. Zhao, X.F. Chen, J.D. Ye, Synthesis and characterization of hydroxyapatite nanobelts and nanoparticles. Mater. Lett 59 (2005) 220-225.
[22]. M.K. Lee, S.J. Lim, C.K. Kim, Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28 (12) (2007), 2137-2146.
[23]. X.D. Zhang, X.Y. Zhang, C.P. Gray, T. Nguyen, P. Hersey, Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by smac/DIABLO release from mitochondria. Cancer Res 61 (19) (2001), 7339-7348.
[24]. X.D. Zhang, J.J. Wu, S. Gillespie, J. Borrow, P. Hersey, Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin. Cancer Res 12 (4) (2006), 1355-1364.
[25]. L.E. van Vlerken, T.K. Vyas, M.M. Amiji, Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm. Res 24 (8) (2007), 1405-1414.
[26]. M. Links, R. Brown, Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev. Mol. Med 1999 (1999) 1-21.
[27]. X. Wen, X. Li, B. Liao, Y. Liu, J. Wu, X. Yuan, B. Ouyang, Q. Sun, X. Gao, Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel. Urology 73 (6) (2009), 1407-1411.
[28]. J. Panyam, V. Labhasetwar, Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol. Pharm 1 (1) (2004), 77-84.
[29]. A. Cossarizza, M. Baccarani-Contri, G. Kalashnikova, C. Franceschi, A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5, 5', 6, 6'-tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem. Biophys. Res. Commun 197 (1) (1993), 40-45.
[30]. H.J. Muenchen, P.J. Poncza, K.J. Pienta, Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3. Urology 57 (2) (2001), 366-370.
[31]. J.M. Chan, L. Zhang, K.P. Yuet, G. Liao, J.W. Rhee, R. Langer, O.C. Farokhzad, PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30 (8) (2009), 1627-1634.
[32]. Q. Xu, Y. Tanaka, J.T. Czernuszka, Encapsulation and release of a hydrophobic drug from hydroxyapatite coated liposomes. Biomaterials 28 (16) (2007), 2687-2694.
[33]. B. Romberg, W.E. Hennink, G. Storm, Sheddable coatings for long-circulating nanoparticles. Pharm. Res 25 (1) (2008), 55-71.
[34]. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, R.K. Jain, Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A 95 (8) (1998), 4607-4612.
[35]. F. Yuan, M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, R.K. Jain, Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 55 (17) (1995), 3752-3756.
[36]. G.J. Charrois, T.M. Allen, Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim. Biophys. Acta 1609 (1) (2003), 102-108.
[37]. F. Fabbri, G. Brigliadori, S. Carloni, P. Ulivi, A. Tesei, R. Silvestrini, D. Amadori, W. Zoli, Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression. Prostate 70 (2) (2010), 219-227.
[38]. W. Jiang, B.Y. Kim, J.T. Rutka, W.C. Chan, Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol 3 (3) (2008), 145-150.
[39]. X. Huang, X. Teng, D. Chen, F. Tang, J. He, The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 31 (3) (2010), 438-448.
[40]. P. Lassus, X. Opitz-Araya, Y. Lazebnik, Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 297 (5585) (2002), 1352-1354.
[41]. N.M. Mhaidat, Y. Wang, K.A. Kiejda, X.D. Zhang, P. Hersey, Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Mol. Cancer Ther 6 (2) (2007), 752-761.
[42]. Y. Guo, S.M. Srinivasula, A. Druilhe, T. Fernandes-Alnemri, E.S. Alnemri, Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J. Biol. Chem 277 (16) (2002), 13430-13437.
|
Language: | English.
|
Document Type: | Article.
|
Journal Subset: | Pharmacology.
|
ISSN: | 0168-3659
|
DOI Number: | https://dx.doi.org/10.1016/j.jco...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|